There is a pressing need to reconsider clinical drug development and distribution of medicines in a truly global sense. The majority of people who desperately need medicinal products get only an inadequate portion of all that is manufactured. This paper is an appeal to those in the international drug development arena to include some of the poorest countries in their drug development programs. It is also a challenge to health professionals and regulatory authorities in those countries to upgrade clinical trial proce¬dures in order to meet international standards and to provide other incentives that attract clinical trials from international drug companies. As a case study, the status of clinical research in Kenya is documented, ft is shown that the framework for conducting clinical trials exists. Potential sponsors are challenged to seek out clinical trial opportunities in this region in order to benefit from the impressive number of excellent health research professionals and large pools of drug-free patient populations.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Kilama WL. Health challenges in early twenty-first century sub-Saharan Africa; African J Health Sei. 1996,6(1):9–16.
The World Factbook—Kenya, http://www.odci.gov/cia/publications/factbook/ke.html.
Proceedings from the 21st Anniversary Celebration of the Kenya Medical Research Institute. Kenya: KEMRI; 2000.
About this article
Cite this article
Kimanani, E. Current Status of Clinical Trials in Kenya. Ther Innov Regul Sci 36, 31–39 (2002) doi:10.1177/009286150203600107
- Global drug development
- International Conference on Harmonization Good Clinical Practice